“…Some biological markers of brain injury have recently been proposed, including protein S100B, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), cleaved Tau protein (CTP), brain type fatty acid-binding protein (B-FABP), kallikrein 6 (KLK6), ubiquitin C-terminal hydrolase (UCH-L1) and II-spectrin breakdown product 145 kDa (SBDP145), among others. [6][7][8][9][10] Although encouraging results have been published about the potential usefulness of some of these biomarkers in research studies, especially protein S100B, 11,12 there is still limited clinical evidence to allow recommendation of routine implementation for diagnosis and management of patients with MHI. 13,14 Red blood cell (RBC) distribution width (RDW) is a measure of anysocytosis, which is commonly used in combination with mean corpuscular volume (MCV) for investigating the underlying cause(s) of anemia.…”